Novo Nordisk and Vivtex Corporation have announced a partnership to develop oral biologic medicines for obesity, diabetes and associated comorbidities.  Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk, while Vivtex is eligible to receive upfront payments totalling up to $2.1 billion, and tiered royalties on future product sales.  “Novo Nordisk […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!